# Microba Life Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/microba-life-sciences

- Industry: Biotechnology
- Headquarters: Brisbane, Australia
- Website: www.microba.com
- Total disclosed funding: $12M
- Latest round: Series B (Jun 16, 2019)
- Investors on record: 3

## About

Microba Life Sciences Limited is a biotechnology company focused on precision microbiome solutions, offering innovative diagnostics and therapeutic development to enhance health outcomes through advanced technologies.Microba Life Sciences Limited specializes in microbiome analysis and health diagnostics. Founded in 2018 in Brisbane, Australia, the company has executed a total of 6 deals, with the most recent deal occurring on November 29, 2022. The company raised USD 17.8 mn in a TRADE SALE led by Sonic Healthcare Limited, marking the total amount raised to USD 17.8 mn. Gene Tyson is the founder, and Luke Reid serves as the CEO.Microba Life Sciences specializes in precision microbiome solutions that leverage advanced technologies for health diagnostics and therapeutic development. Central to their offerings are the MetaPanel™ and MetaXplore™ platforms, which analyze gut microbiome compositions and provide insights into health and disease. These products cater to medical professionals, researchers, and individuals seeking personalized health insights, especially for conditions such as inflammatory bowel disease (IBD) and autoimmune disorders. Microba's solutions are utilized across North America, Europe, and Asia-Pacific markets, aiming to enhance clinical outcomes through data-driven approaches to microbiome science.In 2023, Microba reported revenue of USD 3.65 mn and an EBITDA of USD -7.98 mn. Revenue generation is facilitated through partnerships and direct offerings related to its diagnostic and therapeutic platforms. Their business model includes subscription services for continuous access to microbiome analysis tools, catering to healthcare providers, researchers, and institutions. Flagship products like MetaPanel™ and MetaXplore™ are integral to their revenue stream, as they provide essential insights that drive clinical and research initiatives.Microba Life Sciences Limited plans to leverage its recent funding of USD 17.8 mn from Sonic Healthcare Limited to advance key therapeutic programs and support international expansion of its testing services. The company is focused on launching new products and expanding into additional markets, specifically targeting increased presence in North America and Europe by the end of 2024. The acquisition will facilitate the scaling of its innovative services and enhance its operational capabilities globally.

## Funding rounds

- Series B, Jun 16, 2019, $6.9M — Thorney Investment Group, Alium Capital Management, Perennial Partners
- Series A, Apr 26, 2018, $5.3M — Alium Capital Management

## Investors

- Alium Capital Management (https://capitalatlas.ai/funds/alium-capital-management) — Series A, Series B
- Thorney Investment Group — Series B
- Perennial Partners — Series B